Cardio Diagnostics (NASDAQ:CDIO) Given New $1.35 Price Target at Benchmark

Cardio Diagnostics (NASDAQ:CDIO) had its target price lowered by Benchmark from $4.00 to $1.35 in a research note released on Friday morning, Benzinga reports. The brokerage currently has a speculative buy rating on the stock.

Cardio Diagnostics Price Performance

NASDAQ:CDIO opened at $0.87 on Friday. The firm has a 50-day moving average price of $1.41 and a 200 day moving average price of $1.51. Cardio Diagnostics has a 12-month low of $0.17 and a 12-month high of $3.56.

Institutional Trading of Cardio Diagnostics

Hedge funds have recently modified their holdings of the company. Vanguard Group Inc. increased its holdings in shares of Cardio Diagnostics by 262.6% during the fourth quarter. Vanguard Group Inc. now owns 232,139 shares of the company’s stock worth $578,000 after buying an additional 168,117 shares in the last quarter. Northern Trust Corp acquired a new stake in shares of Cardio Diagnostics during the fourth quarter worth approximately $115,000. Vontobel Holding Ltd. acquired a new stake in shares of Cardio Diagnostics in the fourth quarter valued at approximately $30,000. State Street Corp acquired a new stake in shares of Cardio Diagnostics in the first quarter valued at approximately $163,000. Finally, Geode Capital Management LLC acquired a new stake in shares of Cardio Diagnostics in the first quarter valued at approximately $290,000. Institutional investors and hedge funds own 8.06% of the company’s stock.

About Cardio Diagnostics

Cardio Diagnostics Holdings, Inc, an artificial intelligence-powered precision cardiovascular medicine company, develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease.